In 2015, China’s pharmaceutical industry entered a period of deep adjustment driven by both policy and market, with four areas of investment opportunity identified by industry institutions.

First, the consistency evaluation of generic drugs reshuffles the industry, favouring quality API and formulation makers; second, pilots of separating prescribing from dispensing expand, opening retail and e-commerce channels; third, SOE reform revitalizes existing assets; fourth, mobile health and wellness management accelerate, opening new tracks for the health industry.

For decoction-piece makers, quality standardization and smart manufacturing are likewise the trend. Yuanshengtai will stay quality-first and advance steadily amid the changes.